population. In Hong Kong, overcrowded living conditions facilitate the transmission of both influenza and pneumococcal infection. Although a 23-valent pneumococcal polysaccharide vaccine (PPV) and a trivalent influenza vaccine (TIV) are available for prevention of pneumococcal and influenza infection respectively, the worldwide rates of uptake of these vaccines have been limited and variable [1] [2] [3] [4] . There has been conflicting evidence on whether receipt of PPV can reduce the risk of community-acquired pneumonia and death among elderly persons, defined as those aged у65 years in most of the studies [5] [6] [7] [8] [9] . The evidence in favor of TIV for prevention of influenza and pneumonia in the elderly population appears to be more robust [10] . In addition, several large, prospective studies in Sweden and the United States have shown an additive beneficial effect of dual vaccination, with additional reductions in the risk of hospitalization for influenza or pneumonia and in death [11] [12] [13] . More interestingly, several studies and reviews have demonstrated that systemic respiratory infection can be associated with a transient increased risk of vascular events [14] [15] [16] [17] [18] . Therefore, we performed a large prospective cohort study to evaluate the impact of dual PPV and TIV vaccination, PPV or TIV vaccination alone, and no vaccination on mortality and on hospital and intensive care unit (ICU) admissions for pneumonia, coronary artery disease, and stroke.
METHODS

Study Design
All patients aged у65 years with chronic illness who attended the outpatient clinics in the Hong Kong West Cluster (HKWC), China, from 3 December 2007 through 30 June 2008 were enrolled in a prospective cohort study. During this period, participants were invited to receive PPV and TIV. All participants were observed until 31 March 2009.
Ethics Statement
This study was approved by the institutional review boards at the University of Hong Kong and Hospital Authority HKWC. Written informed consent was obtained for all participants receiving vaccination, and verbal informed consent was obtained for those participants who refused vaccination to be included in the study.
Study Sites and Participants
The study was conducted at the HKWC, 1 of the 7 major health districts in Hong Kong under the Hospital Authority, which provides public hospital service for all Hong Kong citizens. The HKWC includes an acute care tertiary teaching hospital for the University of Hong Kong and 4 convalescent care hospitals. The HKWC provides hospital and outpatient care for an estimated population of 530,000 persons, of which 13% are aged у65 years. Participants were eligible if they were aged у65 years and had у1 of the following chronic illness: asthma, chronic obstructive pulmonary disease (COPD), coronary artery disease, hypertension, diabetes mellitus, stroke, chronic renal or liver disease, or malignancy. Patients with known allergy to eggs or other components of the study vaccines, those with immunosuppression as a result of underlying illness or treatment, those who had received anticancer chemotherapy or radiation therapy during the preceding 12 months, and HIVinfected patients were excluded. Before enrollment, all participants attended a video session on the potential benefits and adverse effects of the vaccines, with information leaflets provided. After vaccination, the patient's name, Hong Kong resident identification card number, date and status of vaccination, age, sex, and past medical history were recorded in the computer medical system. Subsequent hospitalizations, diagnosis, ICU or coronary care unit (CCU) admissions, and deaths were captured and retrieved from the computer medical system.
Participants were allowed to choose their vaccination strat- 
Primary and Secondary End Points
All enrolled participants were monitored via the computer medical system from the time of vaccination until 31 March 2009 (week 64 from the commencement of study). All diagnosis and comorbidities were standardized on the basis of The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), which was incorporated into the computer medical system with the conditions' respective diagnostic codes. Participants with chronic illness were defined To minimize the potential misclassification of illness by ICD-9-CM codes, the diagnosis and comorbidities were cross-checked with the discharge summaries from the computer medical system against the ICD-9-CM codes. Primary outcome. At week 64, we compared the rate of death due to the following diagnoses: pneumonia (480-486), COPD, asthma, influenza-like illness (487), ischemic stroke, acute myocardial infarction (AMI; 410), and cardiac failure.
Secondary outcomes. At week 64, we compared hospital, ICU, and CCU admissions associated with the diagnoses defined in the "Primary outcome" subsection and also with the diagnoses ischemic heart disease and pneumococcal pneumonia (481; confirmed by positive culture from respiratory specimens). We also compared the frequency of hospitalizations for the outcome diagnosis among the 4 groups over a 9-month period from the time of enrollment.
Confounding factors. To minimize the element of selection bias, the study was performed in the HKWC outpatient clinics, where most patients belonged to the lower socioeconomic strata and had similar levels of education. Patient compliance with medical treatment for their respective underlying disease was checked and reinforced by the clinic nurses at each visit. Underlying covariates that were significantly different among the 4 groups were adjusted in the multivariate analysis. The covariates analyzed included age, sex, smoking history, and the presence of any of the comorbidities mentioned above. Physicians who made diagnoses during subsequent hospitalization of the participants were not among the investigators and were unaware of the patients' immunization status.
Statistical Analysis
Data analysis was performed using SPSS software, version 16.0 (SPSS). The incidence of each event was calculated in personyears. The baseline characteristics of the 4 vaccination groups were compared using the x 2 and Mann-Whitney U tests for categorical and continuous variables, respectively. The incidence of hospitalizations among the 4 groups was compared using the x 2 test. The effectiveness of the vaccine in the prevention of first hospitalization and ICU and CCU admissions for the outcome diagnoses were estimated using multivariable Cox proportional hazard models, which we adjusted for statistically significant covariables. The log-rank test was used to assess the vaccines' effectiveness in the prevention of mortality secondary to the outcome diagnoses. P values !.05 were considered to be statistically significant. (5.1%) received PPV alone, and 25,393 (69.3%) were unvaccinated (Table 1) . Fifty-five percent of the unvaccinated declined vaccination by choice, whereas the remaining 45% were excluded for other reasons stated in the exclusion criteria. All participants in the control groups verbally consented to be included in the study for data analysis. The majority (92.2%) of the recruited persons were community dwelling and had never received either the PPV or the 7-valent pneumococcal conjugate vaccine before. The total duration of follow-up was 45,834 person-years. Before receiving the second TIV dose, 331 participants in the PPV-TIV group and in the TIV-alone group died, and 23 participants did not return for the second TIV dose. The median age of all subjects was 75 years (range, 70-80 years), and 16,611 subjects (45.3%) were male. The baseline characteristics and risk factors associated with poor outcome were similar among the participants in each group (Table 1) , except for sex and the comorbid condition of COPD.
RESULTS
Between
Death
At week 64, compared with the unvaccinated group, persons in the PPV-TIV group had a 35% reduction in the risk of death secondary to the outcome diagnosis (hazard ratio [HR], 0.65; 95% CI, 0.55-0.77; P ! .001), whereas those who received TIV alone had a 22% reduction (HR, 0.78; 95% CI, 0.61-1.00; P p .047) in the risk of death (Figures 1 and 2 ).
Hospitalization and CCU and ICU Admission
PPV-TIV group versus the unvaccinated group. At week 64, dual-vaccinees had a 43% reduction in pneumonia (HR, 0.57; 95% CI, 0.51-0.64; P ! .001) (Figure 3) , a 58% reduction in pneumococcal pneumonia (HR, 0.42; 95% CI, 0.22-0.81; P p .01), a 24% reduction in COPD (HR, 0.76; 95% CI, 0.62-0.95; P p .01), a 54% reduction in asthma (HR, 0.46; 95% CI, 0.25-0.84; P p .01), and a 32% reduction in influenza-like illness (HR, 0.68; 95% CI, 0.51-0.92; P p .01), compared with the unvaccinated group ( Figure 1A) . For cardiovascular and cerebrovascular diagnoses, dual-vaccinees had a 33% reduction in ischemic stroke (HR, 0.67; 95% CI, 0.54-0.83; P ! .001) (Figures 1A and 4) , a 35% reduction in ischemic heart disease (HR, 0.65; 95% CI, 0.54-0.78; P ! .001), a 48% reduction in AMI (HR, 0.52; 95% CI, 0.38-0.71; P ! .001) (Figure 5) , and a 19% reduction in heart failure (HR, 0.81; 95% CI, 0.70-0.94; P p .006) (Figure 6 ), compared with the unvaccinated group. This resulted in a 41% reduction in the rate of CCU admission (HR, 0.59; 95% CI, 0.44-0.79; P ! .001) ( Figures 1A and 7) and a 55% reduction in the rate of ICU admission (HR, 0.45; 95% CI, 0.22-0.94; P p .03) ( Figures 1A and 8 ) among the dualvaccinees.
PPV-TIV group versus TIV-alone group. Compared with subjects who received TIV alone, dual-vaccinees had a 24% reduction in pneumonia (P p .008) (Figures 3 and 9A ) and a 38% reduction in AMI (P p .06) (Figures 5 and 9A) .
PPV-TIV group versus PPV-alone group. Compared with subjects who received PPV alone, dual-vaccinees had a 26% reduction in pneumonia (P p .007) (Figures 3 and 9B) , a 35% reduction in AMI (P p .01) (Figures 5 and 9B ), a 33% reduc- tion in CCU admission (P p .008) (Figures 7 and 9B) , and a 38% reduction in ICU admission (P p .01) (Figures 8 and 9B) .
TIV-alone group versus the unvaccinated group. Subjects who received TIV alone had a 23% reduction in pneumonia (P p .003) ( Figures 1B and 3) , a 31% reduction in COPD (P p .05), and a 44% reduction in influenza-like illness (P p .04), compared with the unvaccinated group.
PPV-alone group versus the unvaccinated group. Subjects who received PPV alone had a 23% reduction in pneumonia (P p .007) ( Figures 1C and 3 ) and a 38% reduction in pneumococcal pneumonia (P p .06), compared with the unvaccinated group.
Frequency of Hospitalization
Dual-vaccinees had a significantly lower incidence of hospitalization overall (222 vs 308 hospitalizations per 1000 personyears; P ! .001) and of hospitalization for pneumonia (73 vs 128 hospitalizations per 1000 person-years; P ! .001), influenzalike illness (10 vs 16 hospitalizations per 1000 person-years; P p .002), ischemic stroke (22 vs 36 hospitalizations per 1000 person-years; P p .001), ischemic heart disease (32 vs 56 hospitalizations per 1000 person-years; P ! .001), AMI (10 vs 21 hospitalizations per 1000 person-years; P ! .001), and heart failure (50 vs 76 hospitalizations per 1000 person-years; P p .001), compared with the unvaccinated group ( Table 2) . Dual-vaccinees had a significantly lower incidence of hospitalization for pneumonia (73 vs 95 hospitalizations per 1000 person-years; P p .003), influenza-like illness (10 vs 15 hospitalizations per 1000 person-years; P p .005), ischemic stroke (22 vs 30 hospitalizations per 1000 person-years; P p .007), ischemic heart disease (32 vs 58 hospitalizations per 1000 person-years; P ! .001), and AMI (10 vs 19 hospitalizations per 1000 person-years; P ! .009), compared with subjects who received TIV alone.
DISCUSSION
We performed a large, prospective cohort study to assess the efficacy of dual PPV and TIV vaccination among a communitybased elderly Chinese population. Previous studies of dual PPV and TIV vaccination have focused on the impact on reduction of mortality secondary to pneumonia, COPD, and invasive pneumococcal disease [4, [6] [7] [8] [9] [10] [11] [12] [13] . Many of the previous studies of TIV or PPV alone did not explicitly state whether the patients might have taken the other vaccine at the same time, potentially confounding the results [4, [6] [7] [8] [9] [10] . Therefore, to our knowledge, this is the first study to have comprehensively investigated the impact of dual vaccination on hospitalization for respiratory, cardiovascular, and cerebrovascular diseases, comparing dual vaccination to receipt of TIV or PPV alone and no vaccination. The results confirmed that dual vaccination in the elderly population significantly reduced the risk of death (Ϫ35%) and CCU (Ϫ41%) and ICU (Ϫ55%) admissions, whereas receipt of TIV alone also reduced the risk of death (Ϫ22%), compared with the no vaccination.
This study demonstrated several important novel findings in the role of dual vaccination in the prevention of cardiovascular and cerebrovascular diseases. Dual vaccination reduced the risk of hospitalizations for ischemic stroke (Ϫ33%), ischemic heart disease (Ϫ35%), AMI (Ϫ48%), and heart failure (Ϫ19%), compared with the rates among unvaccinated persons. A previous study by Nichol et al [16] demonstrated that administration of TIV alone reduced the risk of hospitalization for cardiovascular and cerebrovascular diseases (Ϫ16% and Ϫ19%, respectively). However, the magnitude of reduction was modest when compared with the reduction observed in the dual vaccination group in the current study, leading to a further reduction for pneumonia (Ϫ24%), AMI (Ϫ38%), ischemic stroke (Ϫ19%), and CCU (Ϫ31%) and ICU (Ϫ52%) admission. The initial question raised by Nichol et al [19] , suggesting that a significant proportion of the benefits in protection against respiratory, cardiovascular, and cerebrovascular diseases could be attributable to the PPV, has been addressed by the current study.
The protective effect of dual vaccination is likely to be related to the prevention of acute infection, which can elicit both a systemic and local coronary inflammatory response. A large, retrospective case series [14] demonstrated that systemic respiratory tract infection is associated with a transient increase in the risk of cardiovascular and cerebrovascular events during the first 3 days of infection. A more recent review on the role of acute infection in triggering acute coronary syndrome suggested that the association is complex and multifactorial. This is likely to be a consequence of increased inflammatory activity, prothrombotic conditions, and biomechanical stress on the coronary arteries, disrupting and triggering thrombosis in a preexisting advanced coronary lesion [15] . Both influenza and Streptococcus pneumoniae are the likely cause of this acute infection, especially in elderly persons. A study on 34,000 autopsies showed that, during an influenza epidemic, there was an associated 30% increase in autopsy-confirmed coronary deaths [16] , whereas patients with pneumonia due to S. pneumoniae or Haemophilus influenzae had an increased risk of a concurrent acute cardiac event [17, 18] . The exact mechanism for the increased risk of coronary events is not known, although it was suggested in an animal study that immunoglobulin M antibodies generated from the PPV could impede the uptake of oxidized low-density lipoprotein by macrophages due to the molecular mimicry between S. pneumoniae and oxidized low-density lipoprotein, thereby interrupting atherosclerosis [19] . Prospective, randomized clinical trials suggested that influenza vaccine can reduce the risk of coronary [20] [21] [22] and ischemic cerebrovascular events by 50% [23] , whereas a large case-control study demonstrated [24] that PPV was associated with a 150% decrease in the rate of myocardial infarction 2 years after vaccination. In the current prospective study, we have clearly shown that the effect of PPV and TIV is additive, exerting both a strong short-term and long-term effect on the prevention of cardiovascular and cerebrovascular diseases.
Apart from cardiovascular protection, our study reinforced the findings of previous studies [11] [12] [13] on the effect of dual vaccination against lower respiratory tract infection in elderly persons. Local data from the Hong Kong Centre for Health Protection (CHP) suggested that the pathogenicity of the influenza A virus circulating during the study period showed no differences when compared with other years [25] . Frequency of hospitalization for pneumonia after dual vaccination was reduced from 128 to 73 hospitalizations per 1000 person-years, compared with the rate among unvaccinated persons. It also reduced the risk of hospitalizations for pneumococcal (58%) and overall (43%) pneumonia. This risk reduction is additive between the PPV and TIV. Nevertheless, effects of dual vaccination in reduction of hospitalizations for COPD, asthma, and influenza-like illness are likely to be attributed to TIV alone, as explained by a recent study [26] suggesting that respiratory viral infection play a major role in the acute exacerbation of COPD and the effect of bacterial coinfection is minimal.
The successful prevention of respiratory and cardiovascular diseases with dual vaccination resulted in a significant reduction in the risk of hospitalizations and death. All of these can be translated to direct medical care cost savings for elderly persons [27, 28] . Despite the rapidly growing elderly population, vaccination rates for PPV and TIV worldwide remained suboptimal [1, [29] [30] [31] . Public opinion has been cautious with the vaccination policy recommended by the health authority in Hong Kong [32, 33] . With this new evidence of protection against cardiovascular and cerebrovascular diseases, vaccination with PPV and TIV among target populations needs to be encouraged and improved [33] [34] [35] [36] [37] and should be implemented for free [38] . A multifaceted strategy has to be applied to increase immunization rate. Community awareness and education about the potential benefits of dual vaccination with limited risk can be promoted via different mass media [39] and health talk by infectious diseases experts, to improve vaccine use by primary care providers, health care staffs, and patients prior to hospital discharge. There were several limitations of this study. First, the participants were not randomized because of ethical reasons. SecDownloaded from https://academic.oup.com/cid/article-abstract/51/9/1007/292115 by guest on 09 March 2019 ond, there was a relatively short follow-up period because of the unexpected emergence of the novel pandemic (H1N1) virus. Thus, the full beneficial effect of the dual vaccination remained to be expressed. Another limitation is that health-conscious persons may be the one who accept the vaccines, whereas nonhealth-conscious ones refuse. Differences in outcome could, therefore, be due to other factors that flow from lifestyle. Potential confounding factors including the participants' diet and exercise habits were not available for analysis and immunocompromised patients were not assessed. There was also a potential misclassification of illness using ICD-9-CM codes for diagnosis, although this was minimized by cross-checking the diagnosis against the discharge summary. Despite these limitations, the conclusions drawn from this large prospective cohort study are highly valid as the comparison was made among participants from 4 groups of different vaccination status in a population of similar baseline characteristics, risk factors, socioeconomic strata [40] , educational level, and all participants had not received PPV before. Because this study included only elderly persons with chronic illness, the results may not be generalized to the whole elderly population until completion of further study of healthy elderly subjects.
In conclusions, this study has provided strong evidence that dual vaccination with PPV and TIV protect elderly persons with chronic illness against hospitalization for respiratory, cardiovascular, and cerebrovascular diseases, thereby reducing the risk of CCU and ICU admission and of death. This risk reduction is superior to TIV or PPV alone. Dual vaccination with the PPV and TIV with the pandemic (H1N1) virus strain incorporated is an important considerations for both elderly persons and younger at-risk persons. After findings from this study were vetted by the CHP of Hong Kong, the government announced free pneumococcal vaccination for elderly persons with chronic illness in addition to the free influenza vaccination.
